FDA Grants Emergency Use Authorization for InflaRx COVID-19 Drug in Critically Ill Patients

The U.S. Food and Drug Administration in White Oak, Md., on July 20, 2020. Sarah Silbiger/Getty Images

Biopharmaceutical company InflaRx NV’s monoclonal antibody has been granted emergency use authorization (EUA) by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults.

The FDA said on April 4 that it had issued the EUA for the use of Gohibic, a brand name of vilobelimab, a monoclonal anti-human complement factor C5a antibody, to be injected into hospitalized adults when initiated within 48 hours of them receiving artificial life support.